ClinicalTrials.gg
CompletedNCT06164977CTO_BVSUpdated Jun 11, 2025

Chronic Total Coronary Occlusion Treatment Results 6 Years After Bioresorbable Scaffold Implantation

An interventional study of Percutaneous coronary intervention. in Angina Pectoris, Coronary Artery Disease and Occlusion, Coronary, sponsored by Pauls Stradins Clinical University Hospital. Completed at 1 site in Latvia. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by Pauls Stradins Clinical University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 years 9 months after the study started (first participant enrolled Feb 2017, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Sex
All
01

Study summary

Aim of the study is to evaluate chronic total coronary occlusion treatment results 6 years after bioresorbable scaffold implantation by quantitative coronary analysis, intravascular ultrasound and optical coherence tomography.

Read the detailed description

The study aims to assess the outcomes of treating chronic total coronary occlusion (CTO) using bioresorbable scaffolds six years after implantation. The evaluation employs quantitative coronary analysis (QCA), intravascular ultrasound (IVUS), and optical coherence tomography (OCT) as invasive imaging tools. Clinical follow-ups were conducted at one and six years post-implantation to ensure a comprehensive understanding of the long-term safety and feasibility of bioresorbable scaffold implantation for CTO.

The primary outcome measure is defined as the target lesion failure of the treated chronic total coronary occlusion segment. Target lesion failure typically encompasses a composite endpoint that includes clinical events such as cardiac death, target vessel myocardial infarction, and clinically-driven target lesion revascularization.

The use of QCA allows for the quantitative assessment of the coronary arteries, providing measurements of vessel diameter and lesion length. IVUS is employed to obtain detailed images of the vessel wall, helping to visualize the morphology of the treated segment and assess the presence of any complications such as stent malapposition or edge dissections. OCT, with its high resolution, allows for detailed imaging of the coronary artery, providing information on plaque composition and stent apposition.

By combining these invasive imaging tools with clinical follow-ups at specified intervals, the study aims to provide a comprehensive evaluation of the long-term efficacy and safety of bioresorbable scaffold implantation in the treatment of chronic total coronary occlusion. The focus on target lesion failure as the primary outcome measure ensures a clinically relevant assessment of the success of the intervention.

02

Conditions studied

  • Angina Pectoris
  • Coronary Artery Disease
  • Occlusion, Coronary

Keywords

  • Atherosclerosis
  • Chronic total coronary occlusion
  • Intravascular ultrasound
  • Optic coherence tomography
03

In context

Angina Pectoris

454 studies on the registry are indexed under Angina Pectoris; 67 are open to participants now.

This study's enrollment of 34 is below the median of 100 across 273 interventional studies indexed under Angina Pectoris.

Browse Angina Pectoris studies →

Lead sponsor

Pauls Stradins Clinical University Hospital is the lead sponsor of 12 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 100% occlusion of a coronary artery for a duration of greater than or equal to 3 months based on angiographic evidence.

Exclusion criteria

Exclusion Criteria:

  • Participant withdrawal from study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Other
    Chronic total coronary occlusion

    Participants who underwent percutaneous coronary intervention for chronic total coronary occlusion revascularization with bioresorbable scaffold.

    Procedure: Percutaneous coronary intervention.

Interventions

  • ProcedurePercutaneous coronary intervention.

    Revascularization of chronic total coronary occlusion.

06

What researchers measure

Primary outcomes

  1. Target Lesion Failure

    Target Lesion Failure (TLF) will be assessed as the number of participants experiencing at least one of the following events during the follow-up period: cardiovascular death, clinically driven target lesion revascularization, target vessel myocardial infarction and stent thrombosis according to the Academic Research Consortium.

    Time frame: 6 years

07

Study locations

1 site
  • Pauls Stradins Clinical University Hospital
    Riga, LV-1002, Latvia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Dec 2023, 82 months.

Of 60 non-industry interventional studies with no phase under Angina Pectoris, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's 82 months is above that.

Counting every sponsor, half of 72 studies reached it within 43 months; a quarter within 18 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2023
First posted
Dec 11, 2023
StartActual
Feb 1, 2017
Primary completionActual
Dec 1, 2023
CompletionActual
Dec 1, 2023
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06164977
Lead sponsor
Pauls Stradins Clinical University Hospital
Responsible party
Sponsor
First posted
Dec 11, 2023
Start date
Feb 1, 2017
Primary completion
Dec 1, 2023
Completion
Dec 1, 2023
Last update
Jun 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion